(Q44961893)

English

Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Maarten J. Postma

4

object named as

Maarten J Postma

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Mark H Rozenbaum

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Albert Jan van Hoek

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Eelko Hak

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

17 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2367-2369

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Impact of the pneumococcal conjugate vaccine on otitis media

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

The effect of cochlear implant use in postlingually deaf adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.01.005

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44961893&oldid=1382129676"